Pharmaceutical company at the commercial stage Therapeutic shield announced Monday that Dr Jose Menoyo is joining his leadership team as vice president and chief medical officer, effective immediately.
The AIM-listed company said that prior to joining Shield, Dr Menoyo was head of U.S. medical affairs at Alexion Pharmaceuticals, a publicly-traded biotechnology company acquired by AstraZeneca in July.
In this capacity, he led the medical affairs and health outcomes and research teams, supporting a number of rare disease launches.
Prior to his role at Alexion, Dr Menoyo was Senior Vice President of Clinical Development and Medical Affairs for ZS Pharma, which was also ultimately acquired by AstraZeneca.
Previous biopharmaceutical experience included leadership roles at Amgen, Genzyme and Sanofi.
Dr Menoyo completed his Internal Medicine and Nephrology Fellowship at Hahnemann University Hospital and Pennsylvania Medical College, and would report to CEO Greg Madison.
“Dr. Menoyo brings more than 25 years of experience in medical affairs, drug development and regulatory leadership within large and small publicly traded biopharmaceutical companies, which includes successful global drug launches and support to marketing, ”said Greg Madison.
“Dr. Menoyo has extensive US and global experience building and leading high performing teams, and his particular and proven expertise in establishing and executing medical business strategies will be of tremendous value to Shield for the launch of Accrufer in the United States. “
Shield also confirmed that, following his May 28 announcement, Tim Watts is stepping down from the board effective September 30 and will no longer have any role with the group as of that date.
“I want to thank Tim for his pivotal role in getting Shield to the point where Accrufer can be launched in the United States and I wish him well for the future.”
At 1241 BST, shares of Shield Therapeutics were down 2.02% to 41.15p.